TriGenex

Maa: Australia

Kieli: englanti

Lähde: Department of Health (Therapeutic Goods Administration)

Aktiivinen ainesosa:

Bifidobacterium infantis, Quantity: 3.2 billion CFU; Bifidobacterium longum, Quantity: 4.1 billion CFU; Bifidobacterium breve, Quantity: 4 billion CFU

Saatavilla:

Biomedica Nutraceuticals Pty Ltd

INN (Kansainvälinen yleisnimi):

Bifidobacterium breve,Bifidobacterium infantis,Bifidobacterium longum

Lääkemuoto:

Capsule, hard

Koostumus:

Excipient Ingredients: microcrystalline cellulose; colloidal anhydrous silica; tricalcium phosphate; tapioca starch; hypromellose; disodium edetate; potable water; potassium acetate; gellan gum

Antoreitti:

Oral

Käyttöaiheet:

Maintain/support general health and wellbeing ; Maintain/support healthy digestive system function ; Maintain/support healthy digestion ; Maintain/support digestive system health ; Maintain/support intestinal good/beneficial/friendly flora ; Helps restore good/beneficial/friendly intestinal/gut/bowel flora ; Maintain/support immune system health ; Maintain/support healthy immune system function

Tuoteyhteenveto:

Visual Identification: ;

Valtuutuksen tilan:

Licence status A

Valtuutus päivämäärä:

2017-06-30